INTEGRATIVE REVIEW: PSORIASIS TREATMENT IN PEDIATRIC PATIENTS

Abstract

Introduction: Psoriasis is a chronic autoimmune disease with a worldwide prevalence ranging from 0.5% to 11.4%2. Approximately one-third of adults who have this change report onset of symptoms in childhood. Despite the harm related to pediatric patients, the treatment of this group still requires regularization. Objective: To synthesize the results obtained from research on current treatments for psoriasis in children, in order to promote the understanding of this subject. Method: Integrative literature review with 8 selected original articles, which were consulted in the databases: Pubmed and Scielo. Controlled Health Science Descriptors (DeCS) and their corresponding English language that make up the Medical Subject Headings (MeSH) were used: “Psoriasis”; “Treatment”; “Pediatric”; “Drug”. Results: The explored studies addressed the drugs secukinumab, etanercept, ixekizumab, adalimumab, Cal/BD foam, apremilast, in order to analyze, depending on the article, the efficacy, tolerability, safety, pharmacogenetics and immunogenicity of pediatric use of such compounds. Conclusion: Most of the analyzed drugs demonstrated significant efficacy and improvement in the symptoms of the disease. However, most of these drugs are regulated for the treatment of psoriasis in adults, and end up being used in the treatment of children, which is not safe, as the mechanism of action and the long-term effects they can have on children are not known. Therefore, it is concluded that more studies and pediatric clinical trials should be carried out to expand the therapeutic spectrum for this age group.